Drug Profile
Anti-cholesterol vaccine - EntreMed
Latest Information Update: 21 Dec 2004
Price :
$50
*
At a glance
- Originator EntreMed
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 21 Dec 2004 Discontinued - Preclinical for Hypercholesterolaemia in USA (unspecified route)
- 29 Apr 2003 EntreMed is set to close a $US10.25 million equity deal to support development of several of its programmes
- 18 Nov 2002 Supended - Preclinical for Hypercholesterolaemia in USA (unspecified route)